Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -120.20% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.88% | +0.57% | +0.67% | +9.27% | +19.37% |
| Weighted Average Shares Diluted Growth | +2.88% | +0.57% | +0.67% | +9.27% | +19.37% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +63.24% | +60.45% | -17.38% | -11.66% | +29.97% |
| Book Value per Share Growth | +0.00% | +0.00% | -21.73% | -21.44% | +10.38% |
| Debt Growth | -96.76% | -96.89% | +863.15% | +799.02% | +31.81% |
| R&D Expense Growth | +62.44% | +76.29% | +76.99% | +12.16% | -2.65% |
| SG&A Expenses Growth | +142.31% | +104.37% | +26.16% | +21.38% | +8.13% |